ArticleCommunications biology2026
Gut microbiota-derived acetate mitigates Escherichia fergusonii-induced gut dysbiosis exacerbating Klebsiella pneumoniae pulmonary infection in mice.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Escherichia fergusonii is an emerging food-borne opportunistic pathogen that disrupts gut homeostasis and exacerbates the severity of other organ diseases. However, the effects of gut colonization by E. fergusonii on the gut-lung axis remain unclear. Here we show that the abundance of Escherichia increases in microbiota-depleted mice and is enriches in patients with K. pneumoniae-associated pneumonia. Both alterations show a statistically significant correlation with the severity of lung infection. In the murine model, gut colonization by E. fergusonii induces specific gut dysbiosis, decreases intestinal and pulmonary acetate levels, and exacerbates carbapenem-resistant K. pneumoniae-induced pneumonia. Notably, fecal microbiota transplantation and acetate administration restore immune responses, ameliorate gut dysbiosis, increase acetate concentrations in intestinal and pulmonary tissues, and improve disease outcomes in mice with pneumonia. This study demonstrates that E. fergusonii-induced gut dysbiosis modifies the gut-lung immune axis in resistant K. pneumoniae-induced pneumonia and proposes a potential intervention strategy involving microbiota-derived acetate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.